Stockscreener 앱 받기
0.3203
1.08%
-0.0035
전일 마감가:
$0.3238
열려 있는:
$0.3326
하루 거래량:
2.22M
Relative Volume:
1.06
시가총액:
$54.66M
수익:
-
순이익/손실:
$-119.76M
주가수익비율:
-0.2373
EPS:
-1.35
순현금흐름:
$-55.17M
1주 성능:
+6.77%
1개월 성능:
-9.34%
6개월 성능:
-60.70%
1년 성능:
-93.14%
1일 변동 폭
$0.319
$0.3362
1주일 범위
$0.3063
$0.39
52주 변동 폭
$0.295
$10.62
Applied Therapeutics Inc Stock (APLT) Company Profile
명칭
Applied Therapeutics Inc
전화
212-220-9226
주소
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
APLT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLT
Applied Therapeutics Inc
|
0.3203 | 54.66M | 0 | -119.76M | -55.17M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.00 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
522.16 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.33 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.02 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.15 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-23 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-02 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-31 | 개시 | William Blair | Outperform |
| 2024-03-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-02-22 | 개시 | Leerink Partners | Outperform |
| 2022-01-04 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-08-27 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-04-22 | 개시 | Goldman | Buy |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2019-06-10 | 개시 | Citigroup | Buy |
| 2019-06-10 | 개시 | Cowen | Outperform |
| 2019-06-10 | 개시 | Robert W. Baird | Outperform |
모두보기
Applied Therapeutics Inc 주식(APLT)의 최신 뉴스
Applied Therapeutics promotes two executives to leadership roles By Investing.com - Investing.com South Africa
Applied Therapeutics Announces New Chief Medical Officer - TipRanks
APLT Announces Key Executive Promotions | APLT Stock News - GuruFocus
Applied Therapeutics Promotes Evan Bailey to Chief Medical Officer - MarketScreener
Applied Therapeutics Announces Key Leadership Appointments | APLT Stock News - GuruFocus
Applied Therapeutics promotes two executives to leadership roles - Investing.com
Applied Therapeutics Announces Key Leadership Appointments - GlobeNewswire
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New Investment in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
California State Teachers Retirement System Purchases 64,316 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics holds annual stockholders meeting By Investing.com - Investing.com Canada
Applied Therapeutics Elects New Director at Annual Meeting - TipRanks
Applied Therapeutics holds annual stockholders meeting - Investing.com
Two Sigma Investments LP Buys New Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics, Inc. (NASDAQ:APLT) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Set Applied Therapeutics, Inc. (NASDAQ:APLT) Target Price at $6.10 - Defense World
Wellington Management Group LLP Boosts Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics, Inc. (NASDAQ:APLT) Shares Acquired by Millennium Management LLC - MarketBeat
Shareholder Rights Advocates at Levi & Korsinsky Investigate Applied Therapeutics, Inc. (APLT) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Applied Therapeutics, Inc. (NASDAQ:APLT) Short Interest Update - MarketBeat
Millennium Management LLC Boosts Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Class Action Filed Against Applied Therapeutics, Inc. (APLT)February 18, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. LawsuitAPLT - ACCESS Newswire
Shareholders of Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
BNP Paribas Financial Markets Grows Stake in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Janus Henderson Group PLC Sells 10,505,737 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Columbia Trustee Got Sued for Securities Fraud — Then Left Her Pharma Firm Under a Cloud - The Intercept
Janus Henderson Group PLC Decreases Stake in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Price T Rowe Associates Inc. MD Sells 986,108 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
William Blair Brokers Increase Earnings Estimates for APLT - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
Vestal Point Capital LP Acquires 10,355,000 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Stock Rating Upgraded by Wall Street Zen - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Applied Therapeutics Inc (APLT): An Important Analyst Insights - Stocksregister
Applied Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug - MSN
Applied Therapeutics’ Rare Disease Treatment Flunks in Late-Stage Trial - NewsBreak: Local News & Alerts
New top-line data from Phase II/III trial of govorestat in CMT-SORD - The Pharma Letter
Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug By Stocktwits - Investing.com India
Applied Therapeutics Presents Full 12-Month Clinical Results and - GuruFocus
APLT Shares Results from INSPIRE Trial on Govorestat at Peripher - GuruFocus
APLT Shares Results from INSPIRE Trial on Govorestat at Peripheral Nerve Society Meeting | APLT Stock News - GuruFocus
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting - The Manila Times
Applied Therapeutics Presents Full 12-Month Clinical - GlobeNewswire
Breakthrough in CMT Treatment: New Clinical Data Shows First-Ever Disease Progression Slowing in 24-Month Study - Stock Titan
Here's Why Amazon Is a Brilliant Buy Now (Hint: It's Not E-Commerce) - The Globe and Mail
Massive News for Apple Stock Investors! - The Globe and Mail
Applied Therapeutics Inc (APLT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Applied Therapeutics Inc 주식 (APLT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Funtleyder Leslie D. | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
14,502 |
6,381 |
390,459 |
| Chinoporos Constantine | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
447 |
197 |
271,436 |
| Funtleyder Leslie D. | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
22,950 |
14,000 |
404,961 |
| Perfetti Riccardo | Chief Medical Officer |
Feb 06 '25 |
Sale |
0.61 |
86,078 |
52,508 |
900,775 |
| Chinoporos Constantine | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
28,117 |
17,151 |
271,883 |
| Funtleyder Leslie D. | Chief Financial Officer |
Aug 22 '24 |
Sale |
5.83 |
13,530 |
78,880 |
277,911 |
| Perfetti Riccardo | Chief Medical Officer |
Aug 22 '24 |
Sale |
5.83 |
22,681 |
132,230 |
986,853 |
| Shendelman Shoshana | President and CEO |
Aug 13 '24 |
Sale |
6.18 |
357,423 |
2,208,874 |
4,810,430 |
| Shendelman Shoshana | President and CEO |
Aug 12 '24 |
Sale |
5.98 |
300,000 |
1,794,000 |
5,167,853 |
| Shendelman Shoshana | President and CEO |
Aug 14 '24 |
Sale |
5.93 |
119,591 |
709,175 |
4,690,839 |
0.39%
0.26%
자본화:
|
볼륨(24시간):